Cargando…

Correction: Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe COVID-19

Detalles Bibliográficos
Autores principales:	Gritti, Giuseppe, Raimondi, Federico, Bottazzi, Barbara, Ripamonti, Diego, Riva, Ivano, Landi, Francesco, Alborghetti, Leonardo, Frigeni, Marco, Damiani, Marianna, Micò, Caterina, Fagiuoli, Stefano, Lorini, Ferdinando Luca, Gandini, Lucia, Novelli, Luca, Morgan, Jonathan P., Owens, Benjamin M. J., Kanhai, Karan J. K., Reljanovic, Gordana Tonkovic, Rizzi, Marco, Di Marco, Fabiano, Mantovani, Alberto, Rambaldi, Alessandro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8238381/ https://www.ncbi.nlm.nih.gov/pubmed/34183767 http://dx.doi.org/10.1038/s41375-021-01329-8

Ejemplares similares

Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe COVID-19
por: Gritti, Giuseppe, et al.
Publicado: (2021)

Endothelial injury and thrombotic microangiopathy in COVID-19: Treatment with the lectin-pathway inhibitor narsoplimab
por: Rambaldi, Alessandro, et al.
Publicado: (2020)

Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease
por: van Rhee, Frits, et al.
Publicado: (2022)

Pentraxin 3 in Cardiovascular Disease
por: Ristagno, Giuseppe, et al.
Publicado: (2019)

P1140: TIME TO TUMOR, SYMPTOMATIC AND LABORATORY RESPONSES FOLLOWING SILTUXIMAB TREATMENT IN IDIOPATHIC MULTICENTRIC CASTLEMAN DISEASE
por: van Rhee, F., et al.
Publicado: (2022)

Worsening of gas exchange parameters at high FiO(2) in COVID-19: misleading or informative?
por: Raimondi, Federico, et al.
Publicado: (2021)

Chest X-ray for predicting mortality and the need for ventilatory support in COVID-19 patients presenting to the emergency department
por: Balbi, Maurizio, et al.
Publicado: (2020)

Characterization of compliance phenotypes in COVID-19 acute respiratory distress syndrome
por: Zacchetti, Lucia, et al.
Publicado: (2022)

Extent and Distribution of Parenchymal Abnormalities in Baseline CT-Scans Do Not Predict Awake Prone Positioning Response in COVID-19 Related ARDS
por: Raimondi, Federico, et al.
Publicado: (2022)

Severity of respiratory failure and outcome of patients needing a ventilatory support in the Emergency Department during Italian novel coronavirus SARS-CoV2 outbreak: Preliminary data on the role of Helmet CPAP and Non-Invasive Positive Pressure Ventilation
por: Duca, Andrea, et al.
Publicado: (2020)

The natural FGF-trap long pentraxin 3 inhibits lymphangiogenesis and lymphatic dissemination
por: Turati, Marta, et al.
Publicado: (2022)

Siltuximab (CNTO 328): a promising option for human malignancies
por: Chen, Runzhe, et al.
Publicado: (2015)

Emerging treatments in Castleman disease – a critical appraisal of siltuximab
por: Koff, Jean L, et al.
Publicado: (2016)

Impact of siltuximab on patient-related outcomes in multicentric Castleman’s disease
por: Sitenga, Jenna, et al.
Publicado: (2018)

Adaptations and Lessons in the Province of Bergamo
por: Fagiuoli, Stefano, et al.
Publicado: (2020)

The yin-yang of long pentraxin PTX3 in inflammation and immunity
por: Daigo, Kenji, et al.
Publicado: (2014)

Long Pentraxin 3 as a New Biomarker for Diagnosis of Hip and Knee Periprosthetic Joint Infections
por: Loppini, Mattia, et al.
Publicado: (2023)

Inflammatory Long Pentraxin 3 is Associated with Leukocyte Telomere Length in Night-Shift Workers
por: Pavanello, Sofia, et al.
Publicado: (2017)

One-year mortality in COVID-19 is associated with patients’ comorbidities rather than pneumonia severity
por: Novelli, Luca, et al.
Publicado: (2023)

Pathogen Recognition by the Long Pentraxin PTX3
por: Moalli, Federica, et al.
Publicado: (2011)

Experience with the use of siltuximab in patients with SARS-CoV-2 infection
por: Meira, Fernanda, et al.
Publicado: (2021)

Bergamo and Covid-19: How the Dark Can Turn to Light
por: Perico, Norberto, et al.
Publicado: (2021)

Complementary Roles of Short and Long Pentraxins in the Complement-Mediated Immune Response to Aspergillus fumigatus Infections
por: Parente, Raffaella, et al.
Publicado: (2021)

The Long Pentraxin PTX3 in Bone Homeostasis and Pathology
por: Parente, Raffaella, et al.
Publicado: (2019)

Editorial: The Role of Pentraxins: From Inflammation, Tissue Repair and Immunity to Biomarkers
por: Bottazzi, Barbara, et al.
Publicado: (2019)

Structural insights into the biological functions of the long pentraxin PTX3
por: Massimino, Anna Margherita, et al.
Publicado: (2023)

A New Surface Plasmon Resonance-Based Immunoassay for Rapid, Reproducible and Sensitive Quantification of Pentraxin-3 in Human Plasma
por: Canovi, Mara, et al.
Publicado: (2014)

Newly diagnosed and previously treated multicentric Castleman disease respond equally to siltuximab
por: van Rhee, Frits, et al.
Publicado: (2020)

A New Approach to the Management of COVID-19. Antagonists of IL-6: Siltuximab
por: Villaescusa, Lucinda, et al.
Publicado: (2022)

Control of Complement Activation by the Long Pentraxin PTX3: Implications in Age-Related Macular Degeneration
por: Stravalaci, Matteo, et al.
Publicado: (2020)

The clinical, laboratory, and radiologic improvement due to siltuximab treatment in idiopathic multicentric Castleman’s disease
por: Min, Gi-June, et al.
Publicado: (2021)

Idiopathic multicentric Castleman disease treated with siltuximab for 15 years: a case report
por: Lang, Evan, et al.
Publicado: (2022)

Long Pentraxin-3 Follows and Modulates Bladder Cancer Progression
por: Matarazzo, Sara, et al.
Publicado: (2019)

Predicting in-hospital mortality from Coronavirus Disease 2019: A simple validated app for clinical use
por: Magro, Bianca, et al.
Publicado: (2021)

Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera
por: Lussana, Federico, et al.
Publicado: (2017)

Patient-reported Outcomes for Multicentric Castleman’s Disease in a Randomized, Placebo-controlled Study of Siltuximab
por: van Rhee, Frits, et al.
Publicado: (2015)

Concurrent Diagnosis of Acute Myeloid Leukemia and Symptomatic COVID-19 Infection: a Case Report Successfully Treated with Azacitidine-Venetoclax Combination
por: Taurino, Daniela, et al.
Publicado: (2021)

Correspondence regarding “Ventilatory efficiency in athletes, asthma and obesity”: different ventilatory phenotypes during exercise in obesity?
por: Borasio, Nicola, et al.
Publicado: (2022)

Glucocorticoids/siltuximab/tocilizumab: Hepatitis-B reactivation following off-label use: 2 case reports
Publicado: (2021)

Siltuximab-Related Favorable Clinical Outcome for a Patient Suffering from Idiopathic Multicentric Castleman Disease
por: Chrysochoou, Stamatios, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_jc1rga6f265ua9762g4epae6cd